BiotechTube

Dupilumab 300Mg Solution for Injection

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pruritus

Conditions

Pruritus

Trial Timeline

Sep 1, 2020 → Sep 6, 2024

NCT ID
NCT04256759

About Dupilumab 300Mg Solution for Injection

Dupilumab 300Mg Solution for Injection is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Pruritus. The current trial status is completed. This product is registered under clinical trial identifier NCT04256759. Target conditions include Pruritus.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04256759Phase 2Completed

Competing Products

20 competing products in Pruritus

See all competitors
ProductCompanyStageHype Score
Nalmefene + PlaceboTharimmunePhase 2
44
SHR0410Jiangsu Hengrui MedicinePhase 1
33
SHR0410 + PlaceboJiangsu Hengrui MedicinePhase 1
33
DNK333 5 mg + Placebo to 5 mg + DNK333 25 mg + Placebo to 25 mg + DNK333 100 mg + Placebo to 100 mg + Betamethasone 4 mg + DNK333 1mg + Placebo to 1mgNovartisPhase 2
52
MR13A9 + PlaceboKissei PharmaceuticalPhase 3
76
MR13A9 + PlaceboKissei PharmaceuticalPhase 2
51
GabapentinPfizerPre-clinical
22
Dupilumab + Placebo + Fexofenadine (loratadine if not available)SanofiPhase 3
76
BLU-5937 + PlaceboGSK plcPhase 2
51
REGN846Regeneron PharmaceuticalsPhase 1/2
40
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 2
49
Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kgHaisco Pharmaceutical GroupPhase 2
49
HSK21542 tablet + PlaceboHaisco Pharmaceutical GroupPhase 2
49
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
74
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
60
Nalbuphine HCL ERTrevi TherapeuticsPhase 1
28
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
60
VLY-686 + PlaceboVanda PharmaceuticalsPhase 2
44
VLY-686 + PlaceboVanda PharmaceuticalsPhase 1
25
Serlopitant + PlaceboVyne TherapeuticsPhase 2
44

Other Products from Regeneron Pharmaceuticals

DupilumabApproved
84
Intravitreal Aflibercept Injection 2mgApproved
84
Intravitreal aflibercept injection 2.0mgApproved
84
PozelimabApproved
84
DupilumabApproved
84